trending Market Intelligence /marketintelligence/en/news-insights/trending/oCMqT-Z0UFq8jRqyXROeZg2 content esgSubNav
In This List

FibroGen appoints Lilly veteran as CEO

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


FibroGen appoints Lilly veteran as CEO

FibroGen Inc. said its board appointed Enrique Conterno as CEO, replacing Jim Schoeneck.

Schoeneck became FibroGen's interim CEO after Thomas Neff, the company's chairman, founder and CEO, died in August 2019.

Conterno previously was the senior vice president at Eli Lilly and Co. and retired from the pharmaceutical giant at the end of 2019.

San Francisco-based FibroGen discovers, develops and commercializes treatments for chronic and life-threatening conditions such as anemia, idiopathic pulmonary fibrosis and pancreatic cancer.